News search

E.g., 22/11/2024
E.g., 22/11/2024
imagen
About the CNIC
23 Oct 2024

The National Center for Cardiovascular Research (CNIC), and the Health Research Institute of Hospital 12 de Octubre (i+12), representing SERMAS, are actively participating in JACARDI through different pilot projects

Cardiovascular risk factors (particularly metabolic syndrome, insulin resistance, and diabetes) alter coronary microvascular function and increase the risk of atherosclerotic disease, which itself leads to changes in the coronary microcirculation.
Research
19 Sep 2024

A study from CNIC reveals how risk factors and subclinical atherosclerosis affect heart microcirculation in asymptomatic middle-aged individuals. The research, published in JACC: Cardiovascular Imaging, highlights the importance of assessing the heart vessels' ability to regulate blood flow and predict future cardiovascular risk

CNIC researchers
Research
30 Aug 2024

Two studies carried out at the CNIC provide key information about a newly identified cardiovascular risk factor, clonal hematopoiesis, and its treatment with the ancient medication colchicine

About the CNIC
15 May 2024

Globally, cardiovascular diseases due to atherosclerosis – the build-up of plaque in arteries – are the leading cause of death. A new Danish-Spanish research collaboration aims to develop methods to detect atherosclerosis at earlier ages and encourage prevention. Denmark’s Novo Nordisk Foundation has granted up to EUR 23 million to cover the first 2.5 years of the REACT initiative. The initiative is expected to run for 8 years in total


About the CNIC
9 Feb 2024

The National Center for Cardiovascular Research Carlos III (CNIC) is excited to announce the upcoming edition of the CNIC Conferences

Carlos Torroja, Jacob F. Bentzon, Paula Nogales, Laura Carramolino, Vanessa Cumbicus, Daniel Morales, Ana Dopazo, Verónica Labrador y Alberto Benguria
Research
1 Feb 2024

A study published in Nature Cardiovascular Research reveals smooth muscle-derived cells as a new target for reducing the size of atherosclerotic plaque. The results open up new avenues for the design of treatments to enhance the beneficial effect of cholesterol-lowering drugs